KEY TAKEAWAYS
- The study aimed to advance molecular biology for accurate diagnosis and treatment, addressing the lack of effective ovarian cancer markers.
- The review evaluated cell-free DNA methylation for precise diagnosis, prognosis monitoring, and treatment guidance in ovarian cancers.
Ovarian cancer is the most lethal malignancy in the female reproductive tract. Due to the lack of effective diagnostic markers, 75% of cases are diagnosed late, resulting in a 5-year survival rate of only 50%. Advancements in molecular biology are crucial for precise ovarian cancer diagnosis and treatment.
Yajuan Gao and the team aimed to advance molecular biology for precise diagnosis and treatment, addressing the absence of effective ovarian cancer markers.
The study reviewed multiple randomized clinical trials centered on ovarian cancer. It examined advancements in molecular biology and diagnostic techniques for precise diagnosis and treatment of the disease.
The results revealed that liquid biopsy, an innovative method for detecting malignant tumors, has garnered increasing attention in recent years. Liquid biopsies based on cell-free DNA assays show potential in characterizing tumor heterogeneity and monitoring tumor recurrence.
DNA methylation influences numerous biological functions and diseases, particularly in early cancer stages. This has led to the emergence of cell-free DNA methylation profiling as a sensitive and noninvasive technique for identifying cancer origins. It holds promise as a biomarker for early screening, recurrence monitoring, and prognostic evaluation of cancer.
The review concluded that recent advancements and challenges in cell-free DNA methylation analysis were evaluated for diagnosing, monitoring prognosis, and assessing therapeutic responses in managing ovarian cancers. The aim was to provide guidance for precise diagnosis and treatment of the disease.
No funding was received.
Source: https://pubmed.ncbi.nlm.nih.gov/38764160/
Gao Y, Zhou N, Liu J. (2024). “Ovarian Cancer Diagnosis and Prognosis Based on Cell-Free DNA Methylation.” Cancer Control. 2024 Jan-Dec;31:10732748241255548. doi: 10.1177/10732748241255548. PMID: 38764160; PMCID: PMC11104031.
